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ABSTRACT
EVALUATION OF BERRY EXTRACTS ON INTESTINAL DIGESTIVE
ENZMYES AND SUGAR TRNASPORTERS
MAY 2017
JUNGBAE OH, B.S, UNIVERSITY OF MASSACHUSETTS AMHERST
M.S, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: DR. Young-Cheul Kim

Diabetes mellitus affects over 8% of the world population, with the great majority
having type 2 diabetes mellitus (T2DM). T2DM is characterized by postprandial
hyperglycemia and has been identified as key causes of morbidity and mortality with
substantial health care costs due to its complications. Therefore, managing postprandial
hyperglycemia can be an important and practical approach to reduce premature
morbidity and mortality and economic loss. The causes of T2DM are multifactorial and
include both genetic and environmental factors. Also, increased oxidative stress can be
influenced on the prevalence of T2DM. However, sedentary lifestyle and high-calorie
diets are considered as major contributing factors for the development of T2DM. In
particular, consumption of high sucrose elevates blood glucose level dramatically. Thus,
artificial sweeteners were extensively used, however artificial sweeteners are also
increased the prevalence of T2DM. One of the therapeutic approaches to attenuate
hyperglycemia is to inhibit intestinal ɑ- glucosidase enzyme and suppress glucose
transporters that regulate intestinal glucose digestion and absorption. In recent studies,
consumption of fruits and vegetables has been shown to decrease postprandial
iv

hyperglycemia and risk of T2DM by inhibiting carbohydrate digestion and absorption
in the small intestine due to their bioactive compounds. Therefore, there is an increased
interest to find the natural sources to prevent T2DM. In particular, demands of berry
fruits are increased steadily due their natural antioxidants and bioactive compounds.
The antidiabetic effects of various berry extracts or berry mixture in pre-clinical and
clinical studies were shown. However, the underlying pathways of individual berries at
the molecular level are still unclear. Also, it has not been investigated whether berries
can manage the plasma glucose with dietary factors. It may be possible that beneficial
effects of berry consumption could be through inhibiting carbohydrate digestion and
absorption in the small intestine and it can be applied to dietary strategy so that
postprandial hyperglycemia can be managed effectively.
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CHAPTER 1
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a metabolic disorder and one of the major global
health problems in the modern era [1]. According to CDC reports, 8.3% of the
population already had diabetes in 2010 [2], and people with T2DM have about 2 to 4
times higher risk of other complications such as cardiovascular disease (CVD) or stroke
in the United States [3]. A high caloric intake as a high-sugar and high-fat diet combined
with a sedentary lifestyle has been identified as primary determinants in the
development of obesity and T2DM [4]. In particular, a dramatic increase in the
prevalence of obesity and T2DM has also been strongly correlated with sugarsweetened beverages consumption in different population groups [5-8]. In recent years,
non-calorie and non-digestible artificial sweetener (AS), sucralose, have been
extensively used in a variety of food products as an alternative to simple sugars [9].
However, emerging evidence suggest that consumption of AS-contained beverages also
increase the risk of T2DM and metabolic disorders [10, 11], which may be partially
through upregulation of glucose absorption in the small intestine [12]. Although the
global epidemic of obesity mostly explains the increased incidence and prevalence of
T2DM, the precise mechanisms linking obesity to T2DM still remain unclear.
Among the characteristics, postprandial hyperglycemia is a hallmark of T2DM that has
been recognized as an early defect in diabetic patients and prediabetic individuals [13].
Postprandial hyperglycemia can be caused by decreased glucose utilization in
peripheral tissues, resulting in insulin resistance [14]. It can also result from increased
rate of intestinal digestion and absorption from dietary carbohydrates [15]. Therefore,
identifying dietary bioactive components that can delay carbohydrate digestion and
1

absorption in the small intestine to prevent postprandial hyperglycemia is crucial for
the management of T2DM [16].
One of the primary targets of antidiabetic drugs such as acarbose is to inhibit intestinal
carbohydrate digesting enzymes and sugar transport proteins, which have been
demonstrated to be effective in reducing hyperglycemia after a meal [17]. However,
these anti-diabetic drugs are often reported to cause several side effects such as nausea,
vomiting, abdominal cramps [18] or urinary tract infections [19]. Therefore, there has
been increasing interest in investigating dietary bioactive constituents from natural
sources that may modulate carbohydrate digestion and absorption in the small intestine.
Among natural sources, fruits and vegetables have many beneficial nutrients and
phytochemicals that are thought to protect against T2DM [20, 21]. In particular,
demands of cranberries among consumers have been increased due to valuable
bioactive compounds [22] that reduce the risk of CVD [23, 24] and urinary tract
infection [25]. Recent research has also shown an anti-diabetic potential of cranberries
in both clinical studies [26] and in vivo animal studies [27]. Antidiabetic properties of
cranberry consumption may result from delayed digestion and absorption of
carbohydrates in the small intestine. Several in vitro studies reported that cranberry
extracts and its bioactive compounds inhibit yeast ɑ-glucosidase activity [28] as well
as rat ɑ-glucosidase activity [29]. In addition, berry mixtures prepared from several
berries including cranberries have also shown decreased glucose uptake by inhibiting
glucose transporters in Caco-2 intestinal cells [30].
Among many different types of berries, blackberry extracts have been reported to have
hypoglycemic effects in animal studies [31, 32] and in vitro studies, where blackberries
inhibited yeast ɑ-glucosidase activity [33]. However, postprandial anti-hypoglycemic
2

effects of blackberries have not been studied in in vivo settings.
Dietary polyphenols have received immense attention among nutritionists, researchers,
and consumers due mainly to their important roles in human health such as disease
prevention and health promotion. Among the wide range of polyphenols, the most
abundant polyphenols present in berries are anthocyanidins, proanthocyanidins,
flavanols, and phenolic acids [34]. Those biological substances in berries have been
demonstrated to have health benefits in humans with strong antioxidant and antiinflammatory activities [35-37]. Furthermore, recent research has shown an antidiabetic
potential of dietary berry polyphenols by inhibiting glucose uptake in human Caco-2
intestinal cells [30, 38]. This may indicate that quantity as well as compositions of berry
polyphenols is important to achieve health benefits. While there is some evidence from
the published studies that cranberries and blackberries or their bioactive compounds
inhibit both yeast and rat ɑ-glucosidase enzyme activity, it is currently unclear whether
cranberries and blackberries exert inhibitory effects on ɑ-glucosidase activity in human
cell models of intestinal absorptive function such as Caco-2 intestinal cells. Moreover,
the underlying molecular mechanisms of individual berries on intestinal carbohydrate
digestion and absorption are not well understood. Although several studies have
evaluated the antidiabetic potential of various berries, dietary conditions such as in the
presence of dietary carbohydrates and AS were not considered. Therefore, it is not
known whether cranberries and blackberries may suppress intestinal digestion and
absorption of carbohydrates in the presence of various dietary carbohydrate sources.
The overall goal of this study was to identify potential role of berries as part of a dietary
strategy and molecular mechanisms so that postprandial hyperglycemia can be
managed effectively and the need for pharmacotherapy could be greatly reduced. The
aims of the study were (1) to determine the extent to which cranberry extracts (CBE)
3

and blackberry extracts (BBE) regulate intestinal ɑ-glucosidase and/or gene expression
of glucose transporters; (2) whether this correlates with the level of glucose uptake
using human Caco-2 intestinal cells; and (3) investigate whether CBE and BBE
modulate intestinal ɑ-glucosidase and glucose transporters in the presence of dietary
carbohydrates and AS.
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CHAPTER 2
LITERATURE REVIEW
2.1 Trends of type 2 diabetes (T2DM): Global epidemic
T2DM is a metabolic disorder of fat and glucose metabolism and is the most common
form of diabetes [1]. The estimated worldwide prevalence of T2DM has continued to
increase dramatically during the past two decades [39]. According to World Health
Organization (WHO), the prevalence of diabetes in adult population worldwide is 8.5%
in 2014 and is about two times higher compared to1980 [40]. In addition, it is estimated
that over 360 million people would have T2DM by the year 2030 [41].
The rising prevalence of T2DM is especially notable in low and middle-income
countries [42]. For example, the prevalence of T2DM in developing countries in Asia
has increased three to five folds during the past 30 years and now accounts for about
60% of the global diabetic population. As this trends will continue to increase at this
rate, this will certainly be a major global health issue [43]. While the rise of T2DM has
been mostly observed in the adult population, increasing prevalence of T2DM in youth
will become a serious new T2DM epidemic in the 21st century [44]. Until 1990, the
prevalence of T2DM was rarely seen in childhood. However, the T2DM prevalence rate
in youth has been significantly increased within ten years in many other countries [45].
Such dramatic increases of T2DM in low and middle-income class and young ages are
strongly linked to changes in lifestyles with high-calorie diets such as high
carbohydrates and high fat [4].

5

2.1.1 Diabetic complications & economic burden
Diabetes and its complications affect many different organ systems in the body over a
period of time and are a major cause of morbidity and mortality with substantial health
care costs [3]. According to National Health and Nutrition Examination Survey
(NHANES), chronic kidney disease showed the highest prevalence rates (27.8 %),
followed by foot problems (22. 9%) and eye damages (18. 9%), which are classified as
a microvascular disease. While the prevalence rate of microvascular accounts for
around 70%, the mortality rate of diabetic complications is mainly due to macrovascular
disease such as heart disease and stroke, which accounts for 9.8% and 6.6%,
respectively [46].
The burden of diabetes is not only on the health, but also on total health care cost.
According to the American Diabetes Association (ADA), direct and indirect health care
costs for diabetes is estimated over 240 billion dollars in 2012 [47]. Notably,
approximately 40% of the total cost of diabetes is due to treatment of diabetes
complications, and it is estimated that diabetes-related macrovascular disease
accounted for 85% of cumulative costs of diabetic complications [48].
Among the risk factors, hyperglycemia has been identified as a key diagnostic measure
of T2DM and also as major diabetes-mediated health complications. [49, 50]. Thus,
improvement of postprandial hyperglycemia has been effective in attenuating the
macrovascular complications in diabetic patients [51-53]. As a consequence, managing
postprandial hyperglycemia can be an important and practical approach to reduce
premature morbidity and mortality as well as economic burdens.

6

2.2 Pathophysiology of T2DM
The causes of T2DM are multifactorial and include both genetic and environmental
factors that ß-cell function and insulin sensitivity in peripheral tissue [54]. Even though
the numbers of genomes are associated with the prevalence of T2DM, a relatively small
percentage is due to monogenic causes [55]. Epidemiological and experimental
evidence supported that environmental factors including obesity, sedentary lifestyle,
and high-calorie diets are major contributing factors for the development of T2DM [5658]. Notably, high carbohydrates and high fat diets have been shown to induce T2DM
by a combination of pancreatic ß-cell dysfunction and insulin resistance in peripheral
tissues [56].
Under normal physiological conditions, postprandial plasma glucose concentrations are
regulated by the actions of hormones, mainly insulin and glucagon [59]. In the fed state,
pancreatic islet ß-cells secrete insulin in response to plasma glucose level. As a
consequence of insulin secretion, plasma glucose is transported into insulin-sensitive
peripheral tissues via glucose transporters and anabolic metabolism is promoted.
Furthermore, glucagon secretion is inhibited so that lipolysis in adipose tissue and
hepatic gluconeogenesis are suppressed [56].
On the other hand, diets high in carbohydrates and fat cause substantial hyperglycemia,
resulting in increased peripheral tissues insulin resistance and islet ß-cells dysfunction
[60, 61]. In addition, the insulin resistance state is an impairment in the insulinmediated suppression of lipolysis and increased secretion of pro-inflammatory
cytokines in adipose tissue, which in turn aggravate insulin resistance in muscle and
liver. [62]. Numerous studies have demonstrated that elevated plasma free fatty acids
(FFAs) as a result of increased adipose lipolysis impair insulin-stimulated glucose
7

uptake in skeletal muscle. Similarly, elevated FFAs also stimulate hepatic
gluconeogenesis, and endogenous glucose production, which results in decreased
hepatic insulin action with increase the severity of insulin resistance [63].
While reduced glucose utilization by peripheral tissues in insulin resistant state elevates
plasma glucose level, postprandial hyperglycemia can also be directed affected by types
and composition of dietary carbohydrates as well as their intestinal digestion [16]. One
important therapeutic approaches for treating postprandial high blood glucose in T2DM
is to reduce digestion and absorption of dietary carbohydrates. These approaches can
be accomplished by inhibiting carbohydrate hydrolyzing enzymes in the small intestine.
In humans, ɑ-1-4 glycosidic linkage of complex carbohydrates is digested into
disaccharides and oligosaccharides by the action of salivary and pancreatic ɑ-amylase.
Then, disaccharides are further hydrolyzed into monosaccharides by the action of two
subunits of ɑ-glucosidiase, sucrase-isomaltase (S-I) and maltase-glucoamylase (M-G),
in the apical membrane of the small intestine [64].
Absorption of monosaccharides involved transport from the intestinal lumen into
epithelial cells. The glucose and galactose are carried by the sodium-dependent glucose
transporters 1 (SGLT1), while fructose is carried by the glucose transporter 5 (GLUT5).
Glucose, galactose, and fructose are then transported out of the enterocyte via another
hexose transporter, glucose transporter 2 (GLUT2) across basolateral membrane and
into blood [65]. Recent in vivo animal studies suggested that GLUT2 can also be
recruited into the apical side of membrane when the luminal glucose concentration is
high such as occurs in the fed state, enhancing facilitated diffusion [65]. Thus,
retardation of intestinal glucose absorption by inhibiting intestinal glucose transporters
has been targeted to reduce postprandial hyperglycemia.
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2.3 Role of oxidative stress & antioxidant in metabolic disorders & diabetes
Free radicals are reactive atoms that have one or more unpaired electrons that are
associated with many cellular process and human disease, depending on concentration.
[66]. In the human body, oxidants or reactive oxygen species (ROS) including hydroxyl
(OH•), superoxide (O2•–) are generated as a consequence of a variety of normal
physiological metabolism and particularly, cellular oxidative phosphorylation in the
mitochondria [67, 68]. At low concentrations, oxidants or ROS during normal
physiological processes, it acts as stimuli for cell signaling, however, excessive of ROS
or oxidants can react with lipids, proteins, and nucleic acids, causing cellular damages
or apoptosis, and even diabetes and other metabolic complications [67].
Free radicals produced from normal physiological metabolisms are effectively
neutralized by non-enzymatic and enzymatic antioxidants to prevent the propagation of
free radical reactions or oxidants, maintaining the balance of redox system [69]. The
endogenous antioxidant enzymes include superoxide dismutase (SOD), catalase (CAT),
glutathione peroxidase (GPx) and glutathione reductase (GR). SOD is located in the
cytosol (Cu,Zu-SOD) and mitochondria (Mn-SOD) and converts superoxide anion
radicals into oxygen and less toxic hydrogen peroxide [70]. The enzyme Cat present in
the peroxisomes further decomposes hydrogen peroxide into oxygen and water. In
addition, the enzyme GPx degrades both hydrogen peroxide and lipid hydroxy
peroxides in coordination with glutathione reductase in the presence of NADPH as a
cofactor [71].
Recent studies suggest that postprandial hyperglycemia causes overproduction of
superoxide anions via mitochondrial electron transport chain which exceeds
endogenous antioxidant capacity and shift into oxidative stress [49]. Endogenous
9

defense system becomes weakened and unable to counteract the increased ROS,
causing tissue damage through multiple mechanisms. Cellular injury by ROS from
hyperglycemia involves enhanced polyol pathway and increased cellular formation of
advanced glycation end products (AGEs), which are known to activate protein kinase
(PKC) and NF-kB, key mediators of islet ß-cell dysfunction [72]. Therefore,
consumption of exogenous antioxidants has been emphasized to maintain the oxidantantioxidant balance in our body.

2.4 Oral anti-hyperglycemic therapies for Type 2 diabetes
Diet modification with regular physical activities is recommended for preventing the
prevalence of T2DM and is central concepts of any therapeutic programs. Emerging
studies suggested that a significant reduction in the incidence of T2DM through
lifestyle and diet modifications [58, 73]. Because of elevated fasting and postprandial
blood glucose that expose patients to acute and chronic health complications,
pharmacological therapies are mainly targeting glycemic control by the drugs that
increase glucose utilization in peripheral tissues or suppress digestion and absorption
of dietary carbohydrates in the small intestine [74]. Some of the available
pharmacological agents include Sulfonylureas, Biguanides, Thiazolidinedione,
intestinal ɑ-glucosidase inhibitors, and intestinal glucose transporter inhibitors as
discussed below.
2.4.1 Sulfonylureas
Sulfonylureas are the oldest antidiabetic agents and are commonly prescribed for the
treatment of T2DM patients [75]. The most significant effect of sulfonylureas is to
suppress glucagon secretion from pancreatic α-cells and increase plasma levels of
10

insulin secreted from pancreatic β-cells, even though extra pancreatic actions may also
contribute to their anti-hyperglycemia effects [76]. Thereby, treatment with
sulfonylureas decreases plasma glucose and HbA1c level [74]. However, stimulation
of endogenous insulin secretion via sulfonylureas often causes loss of efficacy over
time, which appears to be related to exhaustion of ß-cell function. Hypoglycemia and
weight gain are the two frequently observed side effects of these drugs. In particular,
elderly T2DM patients have over 30% increased the risk of hypoglycemia than younger
patients so that sulfonylureas therapy should be carefully monitored avoided in elder
people with diabetes [77].
2.4.2 Biguanides
Metformin is one of the biguanides that commonly prescribed for T2DM treatment for
long period of time [78]. The precise mode of action of metformin is not fully
understood, but predominant effects of metformin are to suppresses hepatic glucose
production through inhibition of gluconeogenesis [79]. Also, metformin acts as an
insulin-sensitizer that stimulates glucose uptake in peripheral tissues such as skeletal
muscle [80] and decreases the absorption of glucose from the gastrointestinal track.
Therefore, metformin reduces postprandial hyperglycemia without promoting weight
gain. [81]. Side effects associated with metformin therapy are gastrointestinal
complaints and lactic acidosis [82] so that care should be taken from those affected
individuals.
2.4.3 Thiazolidinedione (TZD)
TZDs is one of the oral antidiabetic drugs that improves glycemic control in T2DM
patients through the improvement of insulin sensitivity in peripheral tissues [83]. TZDs
are synthetic ligands for a nuclear receptor, peroxisome-proliferator-activated receptor
11

gamma (PPARγ), and the most prominent effect of TZDs is thus mediated by PPARγ
through stimulation of glucose into skeletal muscle and adipose tissue, a process which
requires insulin [84]. The major side effects of TZDs are primarily associated with
weight gain and edema. In some cases, TZDs are reported to increase the risk of heart
failure in patients with T2DM [85]. Because of these reported adverse events, the
therapy needs to be prescribed with caution and more studies are in needed for its safety.
2.4.4 Intestinal ɑ-glucosidase inhibitors (AGIs)
Acarbose, Voglibose, and Miglitol are ɑ-glucosidase inhibitors (AGI) that have been
prescribed for managing postprandial glucose level in pre-diabetic and diabetic patients
[86]. AGIs act as competitive and reversible inhibitors of the ɑ-glucosidase enzyme,
which delay intestinal digestion and absorption of carbohydrates and mitigate rapid
spike of plasma glucose level after a meal [87]. AGIs are considered to be safe and
effective because it is rarely absorbed in our body. Due to AGIs regulation of
postprandial hyperglycemia, AGIs have been shown a significant reduction in the risk
of CVD and hypertension in clinical studies [88]. Moreover, unlike sulfonylureas, AGIs
do not affect plasma insulin levels. As a result, they do not cause hypoglycemia when
used alone. These agents are not usually used for primary therapy and most useful in
combination with other drugs. Gastrointestinal side effects are common and the major
complaints are bloating, flatulence, diarrhea, abdominal discomfort, and pain [18].
2.4.5 Intestinal glucose transporter inhibitors
SGLT1 is essential for intestinal glucose and galactose absorption and inhibitors such
as sotagliflozin (LX4211) have been reported to hold promise in improving glycemic
control by retarding postprandial glucose peaks in T2DM [19]. The efficacy of
sotagliflozin has been encouraging as it effectively reduces blood HbA1c and glucose
12

levels, suggesting potential efficacy in T2DM [89]. In particular, a dual inhibitory
action of sotagliflozin on intestinal SGLT1 and SLGT2 would provide unique insulinindependent mechanisms to treat T2DM [89]. Hypoglycemia and urinary track
infections are notable side effects due to increased delivery of sugars to the distal region
of the small intestine and colon [19]. While promising from a clinical profile of
postprandial plasma glucose reduction, longer term studies with larger sample sizes are
needed to fully characterize the efficiacy and safety of the drugs.

2.5 Role of diet & dietary components in diabetes
Recent epidemiological studies suggested that dramatic increases in obesity and T2DM
have been observed in different population groups where consumed high fat and
carbohydrate diets including sugar-sweetened beverage [5-8]. Thus, reducing
carbohydrate and fat-rich meal have been shown to reduce postprandial glucose
response in individuals with T2DM [57, 90, 91].
Artificial sweeteners (ASs) are considered safe and beneficial owing to their noncaloric and non-digestible characteristics. Therefore, AS has been extensively used in
variety food products as an alternative to sugars [9]. Although the impact of ASs on
metabolic diseases is controversial, recent evidence clearly suggested that consumption
of ASs especially artificially sweetened beverages increased the risk of T2DM and
metabolic disorders [10, 11, 92, 93]. The molecular mechanisms of AS on metabolic
disorder and T2DM are yet to be investigated. However, it has been reported that ASs
increase postprandial hyperglycemia by increasing intestinal glucose transporters [12].
For individuals with T2DM, a recommended diet high in fruits, vegetables, and dietary
fiber has proven beneficial in lowering markers related to oxidative stress as well as in
13

managing postprandial hyperglycemia. Fruits and vegetables are primary dietary
sources many essential nutrients and phytochemicals that are recognized to prevent or
delay the risk of T2DM [20, 21]. A variety of phenolic compounds including the family
of flavonoids, flavanols, flavanones, flavones, and anthocyanidins are also found in the
fruits and vegetables [94], which are also abundant source of vitamins and minerals
[95]. The antioxidant properties of fruits and vegetables are due to a chemical structure
of phenolic compounds and aromatic phenolic rings that are able to donate hydrogens
to stabilize free radicals [96]. In addition, phytochemicals in fruits and vegetables have
been shown to inhibit intestinal ɑ-glucosidase activity[97], delaying carbohydrate
digestion and absorption into body [98]. Therefore, primary dietary intervention
strategies employ increased consumption of fruits and vegetable rich in dietary fibers.

2.6 Berries and their roles in health & diabetes
Berry fruits are a rich source of natural antioxidants and also high contents of bioactive
compounds including ascorbic acid, anthocyanins, phenolic acids, flavanols, flavonols
and tannins [99-101]. Due to high amounts of bioactive and health-promoting
compounds, berries are widely recognized as functional products that provide health
benefits beyond basic nutrition as well as prevent metabolic disorders.
Several intervention studies have investigated the effects of different berries on CVD
in healthy humans or people with CVD risk factor. Those studies suggested that berry
fruits significantly decrease postprandial oxidative stress and low-density lipoprotein
oxidation, suggesting that berry intake may prevent the incidence of CVD. [102-105].
Currently, the impacts on glucose metabolism have been limited although recent in vitro
studies indicate potential effects of berry extracts at the level of the small intestine.
14

Recent evidence demonstrated that consumption of berries or berry mixture
significantly reduced postprandial hyperglycemia in healthy individuals [106-109]. For
example, bilberry extracts have been reported to ameliorate hyperglycemia and insulin
sensitivity in T2Dm mice via activation of AMP-activated kinase (AMPK) [110]. In
addition, various berry extracts and polyphenols derived from berries can inhibit starch
digestive enzymes and glucose transporters in the gastrointestinal track in vitro [111].
Many studies so far have investigated the effects of bioactive polyphenols isolated from
berries or berry mixture on starch digestive enzymes and glucose transporters. It is thus
possible that beneficial effects of berry consumption could be through there and/or
other cellular targets that may aid in reducing postprandial glucose levels and enhancing
insulin sensitivity, which could support the use of berries or berry extracts to manage
metabolic disorders. Further studies of the effect of berry consumption on gene
expression are valuable to identify potential mechanisms of action.
2.6.1 Cranberries
The America cranberries (Vaccinium macrocarpon) is one of the berries commonly
consumed in America, and over 90% of global cranberries are produced in global [112].
Cranberries have been known to be rich sources of phytochemicals. Currently, over 150
individual phytochemicals including anthocyanins have been identified [113]. Several
human studies provide evidence for effect of cranberry bioactive on chronic disease. In
particular, cranberries are well known to reduce the risk of urinary tract infections [114,
115] and CVD [23, 24] that led to the inclusion of cranberries to modifications. Also,
clinical and animal studies from recent years have revealed new health benefits of
cranberry consumption on T2DM prevention although effects of cranberries on
postprandial hyperglycemia are currently limited. It has been shown that consumption
of raw cranberries exhibits a favorable response to plasma insulin and glucose levels in
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people with T2DM [26], and high fructose diet with cranberry powder for 11 weeks
tend to reduce postprandial hyperglycemia in an animal model [27]. Antidiabetic
properties of cranberries may result from delaying intestinal digestion and absorption
of carbohydrates. There is an evidence showing that cranberries inhibit yeast ɑglucosidase activity [28] and a bioactive compound in cranberries, Cyanidin-3galactoside, also suppresses rat ɑ-glucosidase activity [29]. In addition, in both short
and long-term exposure of berry mixture, which derived from several berries including
cranberries, decreased two main glucose transporters, SGLT1 and GLUT2, as well as
glucose uptake in human Caco-2 intestinal cells [30]. While a body of evidence suggest
that glucose absorption across the apical membrane of enterocyte is hindered by berry
polyphenols, the precise contribution of specific bioactive compounds and individual
berries has not been studied. These further studies will warrant identification of
important modulators of the rate of glucose digestion and absorption and thus of plasma
blood glucose levels.
2.6.2 Blackberries
Blackberry (Rubus sp.) is known to have high contents of phenolics including
anthocyanins and ellagitannins, which contribute to potent antioxidant properties and
other biological benefits of blackberries [116]. In vitro studies have shown that
blackberry extracts exhort inhibitory effects of A549 human lung cancer with reduced
neoplastic transformation in in normal epidermal mouse cells [117]. Furthermore,
blackberry extracts have the dose-dependent anti-proliferate effects in various cancer
cell lines including human oral, breast, prostate, and colon cancer cell line [117]. While
anticarcinogenic properties of blackberries have been demonstrated in several in vitro
studies, possible health benefits against such metabolic disorder like blood glucose
regulation and T2DM have not been extensively studied. In particular, it has not been
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studied in relation to postprandial hyperglycemia in a clinical study. However, limited
evidence showed that dietary supplementation of blackberry extracts in rats for 80 days
decreased plasma glucose concentration and increased peripheral tissue insulin
sensitivity [31]. Also, blackberry intake significantly decreased fasting blood glucose
level on diabetic rats [32]. These results indicate that hypoglycemic effects of
blackberries may contribute to decreased the risk of T2DM and it may result from
inhibition of intestinal ɑ-glucosidase activity, which was shown in vitro study [33].
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CHAPTER 3
BERRY EXTRACT EXERT ANTI-DIABETIC EFFECTS VIA INHIBTION OF
α-GLUCOSIDASE AND GLUCOSE TRANSPORTERS IN HUMAN
INTESTINAL EPITHELIAL CACO-2 CELLS

3.1 Abstract
T2DM is a chronic disease characterized by postprandial hyperglycemia. One of the
therapeutic approaches to attenuate hyperglycemia is to inhibit intestinal ɑ-glucosidase
enzyme and/or suppress glucose transporters that regulate intestinal glucose
transporters such as SGLT1 & GLUT2. Berries rich in polyphenol antioxidants have
various health benefits. Although the antidiabetic effects of various berry extracts or
berry mixture in pre-clinical and clinical studies, the underlying pathways at the
molecular level is still unclear. In this study, we investigated antioxidant and
antidiabetic effects of selected berry extracts by determining free radical scavenging
activates, Caco-2 intestinal ɑ-glucosidase activity, glucose uptake and the gene
expression of ɑ-glucosidase and glucose transporters in Caco-2 cells. Total phenolic
contents of berry extracts varied from 28.55 ± 0.06 to 56.15 ± 1.08 gallic acid equivalent
(GAE μg/mL) and correlated with antioxidant capacities. Both cranberry extract (CBE)
and blackberry extract (BBE) at 200 μg/mL concentration significantly decreased
glucose uptake in Caco-2 cells. While mRNA expression and activity of ɑ-glucosidase
were inhibited by CBE and BBE, mRNA expression of SGLT1 and GLUT2 was only
inhibited by CBE. Moreover, CBE and BBE significantly decreased glucose uptake in
the presence of sucrose and AS. Our data suggest that CBE and BBE have different
molecular mechanisms in suppressing hyperglycemia and their effects are mediated by
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inhibiting carbohydrate digestion and absorption.

3.2 Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by
hyperglycemia and has been steadily increased during the past two decades worldwide
[38]. Furthermore, people with T2DM have about 2 to 4 times higher risk of health
complications such as cardiovascular disease (CVD), which is one of the major health
problems in the 21st century [3]. Among the features of T2DM, postprandial
hyperglycemia is a hallmark of clinical manifestations and a major contributor to
metabolic complications [118]. Therefore, controlling postprandial hyperglycemia is
recognized are prime clinical strategy for the prevention of T2DM and related
cardiovascular events [119].
As postprandial hyperglycemia is primarily regulated by the rate of intestinal digestion
and absorption of carbohydrates [16], one of the therapeutic approaches for
postprandial hyperglycemia is to retard intestinal digestion and absorption processes.
In humans, complex dietary carbohydrates are digested into monosaccharides by the
action of ɑ-amylase and ɑ-glucosidiases, mainly sucrase-isomaltase (S-I) and maltaseglucoamylase (M-G), in the apical membrane of the small intestine [64]. Individual
monosaccrides are then transported into enterocytes through glucose transporters,
mainly sodium-dependent glucose transporter 1 (SGLT1) and non-sodium dependent
glucose transporter 2 & 5 (GLUT2, GLUT5). Then, basolateral GLUT2 transports
monosaccrides from enterocytes to the portal circulation [65]. Several epidemiological
studies have shown a strong association between high carbohydrate diets and sugarsweetened beverages with hyperglycemia and T2DM [5-8]. Furthermore, non-digestive
19

and non-absorbable artificial sweeteners (AS), have been extensively used as
alternatives to simple sugars that are shown to increase the risk of T2DM in clinical
studies [10, 11]. A possible mechanism may involve upregulation of glucose absorption
in the small intestine [12]. Therefore, diet modification with reduced consumption of
dietary sugars or AS has been emphasized to help manage postprandial hyperglycemia.
One of the pharmacological approaches to hyperglycemia and T2Dm is to modulate the
intestinal digestion and absorption of dietary complex carbohydrates, decreasing
postprandial blood glucose levels. There are several currently available drugs including
agarose, an inhibitor of intestinal ɑ-glucosidase enzyme and sotagliflozin, an inhibitor
of intestinal SGLT1. These drugs are designed to reduce glucose absorption in the GI
track, and have been shown to be effective in reducing hyperglycemia after a meal [86,
89]. However, these antidiabetic drugs often cause some side effects including
flatulence, abnormal discomfort, diarrhea [18], and urinary tract infections [19].
Therefore, there have been increasing interests in finding dietary bioactive constituents
from natural sources that can delay carbohydrate digestion and absorption in the small
intestine without such adverse effects.
It is well recognized that hyperglycemia induces overproduction of reactive oxygen
species (ROS), which is known to cause both microvascular and macrovascular
complication of diabetes [49]. Elevated oxidative stress also increases the formation of
advanced glycation end-products (AGEs), causing islet ß-cell dysfunction via PKC and
NF-kb pathways. [72]. Therefore, maintaining the balance between antioxidant and
oxidant stress by dietary antioxidants is crucial to prevent hyperglycemia-mediated
health complications.
Phytochemicals that are thought to protect against postprandial hyperglycemia in
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T2DM [20, 21] and one proposed mechanism is through retardation of glucose uptake
at the small intestinal level [30, 38]. The consumption of berry fruits and their health
benefits is a matter of considerable interest. In particular, cranberries have received
much attention from the public due to many health benefits. Recent research has shown
antidiabetic potential of cranberries in both human [26] and animals [27]. Several in
vitro studies also reported that cranberry extracts or its bioactive compounds inhibit
yeast ɑ-glucosidase activity [28] as well as rat ɑ-glucosidase activity [29]. In addition,
berry mixture containing cranberries showed potency of retardation of glucose
absorption of in Caco-2 intestinal cells [30]. Therefore, antidiabetic properties of
cranberries may result from delayed digestion and absorption of carbohydrates in the
small intestine. Among different types of berries, blackberries have been reported to
have higher antioxidant capacity than cranberries [120] and exert hypoglycemic effects
in animal studies [31, 32]. Using in vitro models, it was shown that blackberry cultivars
inhibit ɑ-glucosidase activity, which may account for hypoglycemic effects in vivo [33].
However, clinical evidence of postprandial hypoglycemic effects of blackberries have
not been studied.
While cranberries and blackberries have shown the inhibitory effects on both yeast and
rat ɑ-glucosidase enzyme activity, it is currently unclear whether cranberries and
blackberries exert the inhibitory effects on ɑ-glucosidase activity in human Caco-2
intestinal cells and whether the effects are related to total phenolic contents. Moreover,
the underlying molecular mechanisms of individual berries on intestinal carbohydrate
digestion and absorption are not well understood. The published studies evaluated
potential efficacies of various berries without considering dietary factors such as
sucrose and AS. Therefore, we evaluated antidiabetic effects by determining
antioxidant capacity and total phenolic contents of berry extracts as well as rat and
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Caco-2 ɑ-glucosidase activities. In addition, effects of berry extracts on gene expression
of carbohydrate digesting enzymes and glucose transporters are evaluated in the
presence of sucrose or AS as dietary strategies in the prevention and treatment of
postprandial hyperglycemia and T2DM.

3.3 Materials and methods
Freeze-dried blackberry, strawberry, raspberry, blueberry, and cranberry powders were
purchased from (North Bay Trading Co. (Brule, WI, USA). 2,2-Diphenyl-1picrylhydrezyl was purchased from Alfa Aesar. (Ward Hill, MA, USA). Folin-Ciocalteu
phenol reagent, rat intestinal acetone powders, 4-nitrophenyl α-d-glucopyranoside
reagents were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Sodium
acetate, TPTZ (2,4,6-Tri(2-pyridyl)-s-triazine), Iron (III) chloride hexahydrate were
purchased from Santa Cruz Biotechnology. (Dallas, TX, USA). 6-(N-(7-Nitrobenz-2oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (6-NBDG) was purchased from Cayman
Chemical (Ann Arbor, MI). The fast SYBR real-time PCR master mix, Dulbecco’s
modified Eagle’s medium (DMEM), fetal bovine serum (FBS), antibiotics, and trypsinEDTA were purchased from Life Technologies (Grand Island, NY, USA). The specific
primers for quantitative real-time PCR were designed by Primer Quest program, and
purchased from integrated DNA Technologies (Coralville, Iowa, USA). Unless noted
otherwise, all chemicals were purchased from Fisher Scientific Company Co.
(Bridgewater, NJ, USA).

3.3.1 Sample preparations
The extraction procedure was carried out according to the method of Michiels et al.
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[121] with slight modifications. Freeze dried berry powders were extracted with solvent
mixture (Acetone/water/acetic acid; 70:29.5:0.5 v/v) for 1 hr at room temperature in
dark place by using multi vortexer at 1200 rpm. Berry extracts were then filtered with
Whatman filter paper No.3. Remained acetone from sample extracts was removed and
concentrated under reduced pressure at 35°C by using the rotary evaporator. The freezedried powders were stored at – 80 ºC

3.3.2 Cell culture
Human intestinal Caco-2 cells (passage number 75-79) were seeded into cell culture
plates and cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were incubated at
37°C in an atmosphere of 5% of CO2, and media was replaced every 48 hrs. The Caco2 cells were treated with samples at day 8 after confluence. In order to evaluate the
effect of the berry extracts in presence of dietary sucrose or AS, cells were preincubated
in DMEM without 10% of fetal bovine serum for 3 hrs prior to sample treatments.

3.3.3 Total phenolic contents
Total phenolic contents were determined following the procedure previously described
by Blainsket al. [122] with a slight modification. 1 mL of sample was mixed with 10%
(v/v) Folin-Ciocalteu phenol reagent and 2% Na2CO3 at the ratio of 1:1:1. The mixture
was placed in dark place for 60 min and the observance was measured at 750 nm using
Micro-Plate Reader (Molecular devices; Sunnyvale, CA, USA). The amounts of
phenolic compounds were expressed as gallic acid equivalent (GAE μg/mL). Standard
curve was obtained using various concentrations of gallic acid dissolved in water.
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3.3.4 1,1-Diphenyl-2-Picrylhydrazyl (DPPH) radical scavenging activities
The antioxidant capacity was determined by DPPH radical scavenging method as
described by Tailor et al. [123] with some modifications. A sample solution (40 μL) was
mixed with 160 μL of 400 mM DPPH solution in 95% ethanol. Then, the mixture was
incubated for 10 min at room temperature. Absorbance was measured at 517 nm by a
Micro-Plate Reader and compared with controls which contained 40 μL of 50% DMSO
used to dissolve the extract powders. The DPPH radical scavenging activity was
expressed as percent inhibition and calculated based on the formula as follows:
Inhibition (%) = �

∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(517𝑛𝑛𝑛𝑛) − ∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(517𝑛𝑛𝑛𝑛)
� 𝑥𝑥 100
∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(517𝑛𝑛𝑛𝑛)

3.3.5 Ferric reducing ability of plasma(FRAP) assay
Ferric reducing ability of plasma was determined following the procedure previously
described by Benzine et al. [124] with slight modification. FRAP reagent was made
with 300 mM sodium acetate buffer (pH 3.6), 10 mM TPTZ (2,4,6-Tri(2-pyridyl)-striazine) and 20 mM Iron (III) chloride hexahydrate with 10:1:1 ratio. TPTZ and Iron
(III) chloride hexahydrate were dissolved in 40 mM hydrogen chloride before the
experiment. 1.9 mL of FRAP reagent was mixed with in 100 ul of sample and incubated
at room temperature for 30 min. The absorbance was measured at 593 nm by a MicroPlate Reader and compared with controls which contained 50% DMSO. Ferric reducing
ability of plasma was expressed as ascorbic acid equivalent (AAE μM/mL). Standard
curve was obtained using various concentrations of ascorbic acid.
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3.3.6 Nitric oxide (NO) assay
Nitric oxide was determined following the procedure previously described by Tsikas et
al. [125] with slight modification. 1 mL of sodium nitrite (10 mM) was mixed with 1
ml sample and pH was adjusted to 1.2 in the final volume of 10 mL. The mixture was
then incubated at 37 °C for 1 h. After one hour, 0.4 ml of Griess reagent and 1 mL of
mixture were mixed with 2.5 mL of 2% acetic acid. The mixture was then incubated for
15 min until pigment was expressed. The absorbance was measured at 520 nm by a
Micro-Plate Reader and compared with controls which contained 1 mL of 50% DMSO.
The nitric oxide inhibitory activity was expressed as percent inhibition and calculated
based on the formula as follows:
Inhibition (%) = �

∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(520𝑛𝑛𝑛𝑛) − ∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(520𝑛𝑛𝑛𝑛)
� 𝑥𝑥 100
∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(520𝑛𝑛𝑛𝑛)

3.3.7 Rat ɑ-glucosidase activity
Rat intestinal α-glucosidase activity was determined using the substrate, 5 mM of pnitrophenyl-α-D-glucopyranoside (pNPG), as demonstrated by Kwon et al. [36] with a
slight modification. Rat-intestinal acetone powder suspending in 0.9% of saline and
vortexed for 6 min at 4 °C, centrifuging (13,000× g, 15 min, 4 °C), and supernatant was
collected for the experiment. 100 μL of rat intestinal α-glucosidase solution (1.0 U/mL)
was then mixed with 50 μL of sample solution and 50 μL of substrates or buffer, and
was the mixture further incubated at 37 °C for 30 min. After incubation, Na2CO3 was
added to stop the reaction. The absorbance was recorded at 405 nm by Micro-Plate
Reader and compared with controls. The rat α-glucosidase inhibitory activity was
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expressed as percent inhibition and calculated based on formulation as follows:
Inhibition (%) = �

∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(405𝑛𝑛𝑛𝑛) − ∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(405𝑛𝑛𝑛𝑛)
� 𝑥𝑥 100
∆𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(405𝑛𝑛𝑛𝑛)

3.3.8 Caco-2 ɑ-glucosidase activity
Caco-2 ɑ-glucosidase activity was determined following the procedure previously
described by Yu et al. [126]. Caco-2 cells were seeded into 6-well plates and collected
with phosphate buffered saline (PBS) at 8 day after confluence. Caco-2 lysate (100 uL),
sample solution (50 uL), and 5 mM pNPG solution or PBS were placed in 96-well plates.
The mixture was then further incubated at 37 °C. After incubation, Na2CO3 was added
to stop the reaction. The absorbance was measured at 405 nm using Micro-Plate Reader.
The Caco-2 α-glucosidase inhibitory activity was expressed as percent inhibition and
calculated same as ɑ-glucosidase activity.

3.3.9 Caco-2 sucrase and glucoamylase activity
Sucrase and glucoamylase activity were determined following the procedure previously
described by Oh et al. [16] with a slight modification. Differentiated Caco-2 cells were
harvested with PBS. The Caco-2 cell lysate was then mixed with 200 mM of sucrose
for testing sucrase inhibitory activity or 1% of starch for testing glucoamylase
inhibitory activity. Degree of enzymatic activity was determined by amount of glucose
released from substrate in a given period of time by using Invitrogen glucose
peroxidation kit from Invitrogen. The absorbance was measured at 560 nm by a MicroPlate Reader and compared with control. Caco-2 sucrase and glucoamylase activity
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expressed as percent inhibition and calculated same as ɑ-glucosidase activity.

3.3.10 qPCR
The mRNA expression of Caco-2 cells was evaluated by RT-PCR. Total RNAs from
differentiated Caco-2 cells were isolated by using TRIzol reagent by following the
manufacture instruction. The RNA pellet was dissolved in RNase-free water, and RNA
concentration and purity were measured by using nanodrop machine (Fisher,
Bridgewater, NJ, USA) prior to cDNA synthesis. 1 μg of RNA was synthesized using
RevertAid First Strand cDNA Synthesis kit (Thermo Scientific, Waltham, MA).
Quantitative real time PCR reaction was performed with 100 ng of cDNA and 0.5 μM
of forward and reverse primer with 2X Fast SYBR green Master Mix under 40 cycles.
The expression level of each target gene is normalized to GAPDH and calculation was
followed by delta delta ct calculation method (2ΔΔct). Primers for sodium glucose
transporter 1 (SGLT1, forward (5’- GGG CAG CTT CAG GCA TC -3’) and reverse
(5’- AAA CAG CCA GCC CAG CA -3’)) , glucose transporter 2 (GLUT2, forward (5’ACG GCT GGT ATC AGC AAA C -3’) and reverse (5’- CTG CCT TCT CCA CAA
GGA ATA C -3’)), glucose transporter 5 (GLUT5, forward (5’- GGC TGG GAC TCT
GTG GA -3’) and reverse (5’- CAG CTT CAG CAC GGA GAT G -3’)), sucroseisomaltase (S-I, forward (5’- CCG GTG GCA TTC TGG ATT T -3’) and reverse (5’TAT GCT GGC ATT GCT GGT AG -3’)), maltase-glucoamylase (M-G, forward (5’TGC CTT CAC CAG TGT TT -3’) and reverse (5’- GGG CAC TTC AAA CCT GTT
ATT G -3’)), TAS1R2 (T1R2, forward (5’- GCT GCC CAC CAA CTA CCA -3’) and
reverse (5’- CGC TGT AGG CAG ACA TAG A -3’)), TAS1R3 (T1R3, forward (5’CTG CTT TGG CCT GGT GTG -3’) and reverse (5’- GTG GGA CCA GGG CTG CT
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-3’)), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, forward (5’- GAT
GCT GGC GCT GAG TA -3’) and reverse (5’- GGC AGC GAT GAT GAC CCT TT 3’)) were used.
3.3.11 Glucose uptake
Differentiated Caco-2 cells were pre-incubated with serum free DMEM for 3 hrs.
Medium was then replaced with serum-free high glucose (25 mM) with or without a
sample for 1 hour. After an hour, media was replaced with 6-NBDG for 15 mins. Cells
lysate was prepared with lysis buffer (0.1M potassium phosphate buffer (pH10)
containing 1% Trition X-100) and transferred into 96-well plate. The fluorescence was
immediately measured using micro-plate reader (Excitation=460, emission=540). The
rate of glucose uptake was normalized to control.

3.3.12 Statistical Analysis
All data were presented as the mean ± SD for each assay. Statistical analysis was carried
out using SAS program (University edition SAS Inc. NC. USA) and significance of
each group was verified with One-way analysis of variance (ANOVA) followed by the
Duncan’s multiple range test and the Student’s t-test for comparison of means. p-values
of less than 0.05 were considered to be statistically significant.
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3.4 Results
3.4.1 Total phenolic contents and antioxidant capacity of five berry extracts
Total phenolic contents and antioxidant capacities of five different berries extracts,
blackberry (BBE), cranberry (CBE), strawberry (SBE), raspberry (RBE), and blueberry
(BLBE) extracts were evaluated to correlate the amount of phenolic contents with
antioxidant capacity. As shown in Table 1, the amount of total phenolic contents among
berry extracts varied from 28.55 ± 0.06 to 56.15 ± 1.08 gallic acid equivalent (GAE
ug/mL). BBE showed the highest phenolic contents (28.55 ± 0.06 GAE ug/mL),
whereas BLBE (28.55 ± 0.06 GAE ug/mL) showed the lowest total phenolic contents.
In order to determine antioxidant capacity of five different berry extracts, three different
antioxidant assays, ferric reducing ability power, DPPH radical, and nitric oxide
scavenging activity were performed as shown in Table 1. Ferric reducing ability power
(FRAP) of berry extracts calculated using ascorbic acid equivalent (AAE μM/mL).
Among the five berries, BBE displayed the highest FRAP values (715 ± 20 AAE μM),
and BLBE has the lowest FRAP values (287 ± 9 AAE μM). Antioxidant capacity of
berry extracts against DPPH radicals (2,2-diphenyl-1-picrylhydrazyl) was quantified
and half maximal inhibitory concentration (IC50) was measured. Within five berry
extracts, BBE showed the lowest concentration IC50 (1.15 ± 0.01 mg/mL) which
implicated the highest DPPH scavenging activities. In contrast, CBE and BLBE showed
the lowest DPPH radical scavenging activities (IC50 > 2.5 mg/mL). Antioxidant
capacities of berry extracts against nitric oxide (NO) was also quantified and IC50 values
were measured. Similar to other antioxidant assays, BBE had the highest efficacy for
scavenging nitric oxide (IC50: 2.46 ± 0.08 mg/mL), whereas CBE and BBE showed the
lowest activity (IC50: > 5 mg/mL) for scavenging nitric oxide (Table 1). These results
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indicate that antioxidant capacity is strongly correlated with total phenolic contents

Total Phenolic Contents & Antioxidant Activities of Berry extracts
Equivalent value of berry antioxidants
TPC

FRAP

DPPH

NO

GAE (μg/mL)

AAE (μM/mL)

IC50 (mg/mL)

IC50 (mg/mL)

BBE

56.15 ± 1.08a

715 ± 20a

1.15 ± 0.01

2.46 ± 0.08

SBE

54.90 ± 1.23a

582 ± 16b

1.22± 0.08

2.98 ± 0.16

RBE

34.65 ± 0.63b

450 ± 36c

1.95± 0.16

4.13± 0.03

CBE

33.28 ± 0.57b

339 ± 26d

> 2.5

>5

BLBE

28.55 ± 0.06c

287 ± 9e

> 2.5

>5

Table 1. Total phenolic contents and antioxidant capacity of five different berries.
Results were expressed as mean ± SD of three independent experiments in triplicate.
Different corresponding letters indicate significant differences at p < 0.05 by Duncan’s
test. TPC: total phenolic contents, FRAP: Ferric reducing ability of plasma, DPPH: 2.2diphenyl-1-picrylhydrazyl radical scavenging activity, NO: Nitric oxide inhibitory
activity, GAE: Gallic acid equivalent, AAE: Ascorbic acid equivalent, BBE: Blackberry
extracts, SBE: Strawberry extracts, RBE: Raspberry extracts, CBE: Cranberry extracts,
BLBE: Blueberry extracts.
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3.4.2 Effect of different berry extract on rat and Caco-2 ɑ-glucosidase activity
The effects of different berry extracts on rat ɑ-glucosidase inhibitory activities was
evaluated for screening antidiabetic potential of berry extracts, and 25 μM of Acarbose
was included as a positive control. As shown in Figure 1 (A), all berry extracts dose
dependently increased rat ɑ-glucosidase inhibitory activity. However, CBE and BBE
showed the highest rat ɑ-glucosidase inhibitory activity by 74% and 72% respectively,
while other berry extracts inhibited the rat ɑ-glucosidase activity by around 65% at 5
mg/mL concentration.
Many published studies have investigated antidiabetic effects of various berry extracts
by determining yeast [28] and rat ɑ-glucosidase [29], which is often difficult to
extrapolate the activity of data to humans. Therefore, effects of berry extracts on human
ɑ-glucosidase activity was evaluated by using human Caco-2 intestinal cells. As shown
in Figure 1 (B), effect of berry extracts on Caco-2 ɑ-glucosidase activity showed similar
trends as rat ɑ-glucosidase activity (Data was not included 5 mg/mL concentration due
to all extracts reached 100% inhibition). CBE showed the highest human Caco-2 ɑglucosidase inhibitory activity (95%) at 2.5 mg/mL concentration, followed by black,
and other three berry extracts. However, berry extracts showed higher inhibitory effects
in human Caco-2 cells rather than rat ɑ-glucosidase.
So far, the correlation between total phenolic contents and ɑ-glucosidase activity
remains controversial, however, the amount of phenolic content are believed to
correlate with ɑ-glucosidase inhibitory activities [127]. However, in our study, amount
of total phenolic contents does not seem to correlate with ɑ-glucosidase activity.
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Figure 1. Effects of five different berry extracts on rat and Caco-2 α-glucosidase
activity. Rat and Caco-2 α-glucosidase activity were determined by measuring pnitrophenol released from pNPG at 405 nm. Results are expressed as mean ± SD of
three independent experiments each performed in triplicates. Different corresponding
letters indicate significant differences at p < 0.05 by Duncan’s test. AC: Acarbose, BBE:
Blackberry extracts, SBE: Strawberry extracts, RBE: Raspberry extracts, CBE:
Cranberry extracts, BLBE: Blueberry extracts.
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3.4.3 Effects of CBE and BBE on sucrase and glucoamylase activity
Among five different berries, we selected CBE and BBE based on the highest ɑglucosidase inhibitory activity and total phenolic contents. However, in order to
evaluate the ɑ-glucosidase inhibitory effects of berry extracts at physiological
concentration, we evaluated effects of CBE and BBE on Caco-2 ɑ-glucosidase activity
at low concentration (0 ~ 200 μg/mL). As shown in Figure 2, both CBE and BBE
inhibited Caco-2 ɑ-glucosidase activities in dose dependent manner.
ɑ-glucosidase is a cluster of several enzymes in the small intestine. Among the ɑglucosidases, retardation of sucrase and glucoamylase activity are directly involved in
postprandial hyperglycemia due to sucrose and starch are commonly consumed from
our diet. Therefore, we evaluated effects of berry extracts on sucrase and glucoamylase
activity. As shown in Figure 3, both CBE and BBE suppressed sucrase activities even
at 50 μg/mL concentration and sucrase inhibitory activity were increased dose
dependently. Although the both CBE and BBE showed inhibitory effects of
glucoamlyase at 200 μg/mL concentration, only CBE seems to have glucoamylase
inhibitory effects at 50 to 100 μg/mL concentrations (Figure 4). These data suggest that
CBE and BBE have antidiabetic potentials by inhibiting sucrase and glucoamylase, but
the efficacy of berry extracts on specific enzyme inhibitory effects may differ.
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Figure 2. Effects of CBE and BBE on Caoc-2 ɑ-glucosidase activity. Caco-2 ɑglucosidase activity was determined by measuring p-nitrophenol released from pNPG
at 405 nm. Results are expressed as mean ± SD of three independent experiments each
performed triplicate. Different corresponding letters indicate significant differences at
p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry extracts.
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Figure 3. Effects of CBE and BBE on Caco-2 sucrase activity. Sucrase inhibitory
activity was determined by measuring glucose released from sucrose at 560 nm by using
glucose peroxidation kit. Results are expressed as mean ± SD of three independent
experiments each performed triplicate. Different corresponding letters indicate
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE:
Blackberry extracts.
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Figure 4. Effects of CBE and BBE on Caco-2 glucoamlyase activity. Glucoamlyase
inhibitory activity was determined by measuring glucose released from starch at 560
nm by using glucose peroxidation kit. Results are expressed as mean ± SD of three
independent experiments each performed triplicate. Different corresponding letters
indicate significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts,
BBE: Blackberry extracts
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3.4.4 Effects of CBE and BBE on glucose uptake and gene expression in Caco-2
cells
Berry mixtures have been reported to suppress the glucose uptake by inhibiting glucose
transporters [30], but individual berries were not examined. Individual berry extracts
may have different molecular mechanisms to modify postprandial plasma glucose level.
Hence, we investigated effects of CBE and BBE on glucose uptake as well as gene
expression of glucose transporters and carbohydrate digesting enzymes in the small
intestine.
Physiological effects of CBE and BBE on enterocytes were determined by glucose
uptake using 6-NBDG florescence probe. As shown in Figure 5, both CBE and BBE
significantly decreased glucose uptake at 200 μg/mL concentration. However, only
CBE reduced glucose uptake even at 100 μg/mL concentration.
In order to identify molecular mechanisms of CBE and BBE, glucose transporters,
SGLT1 and GLUT2, and two subunits of ɑ-glucosidase, S-I and M-G, were evaluated.
As shown in Figure 6, both glucose transporters were significantly decreased in the
presence of CBE at 200 μg/mL. Also, both carbohydrate digesting enzymes were
significantly decreased at 200 μg/mL (Figure 7). On the other hand, BBE did not alter
the both SGLT1 and GLUT2 mRNA expression, although BBE significantly reduced
expression of S-I and M-G at 200 μg/mL concentration (Figure 10). These results
suggest that CBE and BBE have different molecular mechanisms to prevent
postprandial hyperglycemia.
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Figure 5. Effects of CBE and BBE on glucose uptake in human Caco-2 intestinal
cells. Human intestinal Caco-2 cells were treated with CBE or BBE extracts for 1hr.
Glucose uptake was determined by measuring fluorescence of 6-NBDG in the cells.
Excitation and emission wavelength for 6-NBDG is 465 nm and 540 nm respectively.
Results are normalized to control group and presented as mean ± SD of three
independent experiments (n=3). CBE: Cranberry extracts, BBE: Blackberry extracts.
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Figure 6. Effects of CBE on glucose transporter expression. Human intestinal Caco2 cells were treated with different concentrations of CBE (0~200 μg/mL) for 1hr.
SGLT1 and GLUT2 mRNA level were normalized to GAPDH as housekeeping genes.
Results are presented relative value compare to the control groups as mean ± SD of
three independent experiments (n=3). Different corresponding letters indicate
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts.
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Figure 7. Effects of CBE on carbohydrate digesting enzyme expression. Human
intestinal Caco-2 cells were treated with different concentrations of CBE (0~200 μg/mL)
for 1hr. S-I and M-G mRNA levels were normalized to GAPDH as housekeeping genes.
Results are presented relative value compare to the control groups as mean ± SD of
three independent experiments (n=3). Different corresponding letters indicate
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts.
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Figure 8. Effects of BBE on glucose transporter expression. Human intestinal Caco2 cells were treated with different concentrations of BBE (0~200 μg/mL) for 1hr.
SGLT1 and GLUT2 mRNA levels were normalized to GAPDH as housekeeping genes.
Results are presented relative value compare to the control groups as mean ± SD of
three independent experiments (n=3). Different corresponding letters indicate
significant differences at p < 0.05 by Duncan’s test. BBE: Blackberry extracts.
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Figure 9. Effects of BBE on carbohydrate digesting enzyme expression. Human
intestinal Caco-2 cells were treated with different concentrations of BBE (0~200 μg/mL)
for 1hr. S-I and M-G mRNA level were normalized to GAPDH as housekeeping genes.
Results are presented relative value compare to the control groups as mean ± SD of
three independent experiments (n=3). Different corresponding letters indicate
significant differences at p < 0.05 by Duncan’s test. BBE: Blackberry extracts.
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3.4.5 Effects of sucrose on small intestinal ɑ-glucosidase, glucose transporters,
and glucose uptake in Caco-2 cells
Dietary sucrose has been considered as a major determinant of postprandial
hyperglycemia. However, effects of sucrose on small intestinal ɑ-glucosidase and
glucose transporters were not well understood in in vitro stetting. Therefore, we selected
the concentrations ranging from 25 mM to 100 mM of sucrose to determine the effects
of sucrose on intestinal digestion and absorption in the small intestine.
In order to determine physiological effects of sucrose on enterocytes, glucose uptake
was performed by using 6-NDBG probe. As shown in Figure 10, there were no changes
until 100 mM of sucrose. When the cells are exposed to 100 mM of sucrose, glucose
uptake was significantly increased by 30%
Sucrose is hydrolyzed into glucose and fructose, which are then transported by glucose
transporters (SGLT1, GLUT2) and fructose transporter (GLUT2, GLUT5) into
enterocytes. As shown in Figure 11, mRNA expression of SGLT1, GLUT2, and GLUT5
was not changed in the presence of 50 mM of sucrose. However, mRNA expression of
these glucose transporters was significantly elevated by around 20~30% at 100 mM of
sucrose compare to control
From Between two subunits of ɑ-glucosidase, only sucrose hydrolyzing enzyme, S-I,
was significantly increased in presence of 100 mM sucrose, whereas starch hydrolyzing
enzyme, M-G, was not altered in the presence of 100 mM of sucrose (Figure 12).
Therefore, 100 mM sucrose were further tested for evaluating effects of CBE and BBE
in presence of dietary sucrose.
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Figure 10. Effects of sucrose on glucose uptake. Human intestinal Caco-2 cells were
treated with different concentration of sucrose for 1hr. Glucose uptake was determined
by measuring fluorescence of 6-NBDG in the cells. Excitation and emission wavelength
for 6-NBDG is 465 nm and 540 nm respectively. Results are normalized to control
group and presented as mean ± SD of three independent experiments (n=3).
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Figure 11. Effects of sucrose on glucose transporter expression. Human intestinal
Caco-2 cells were treated with different concentrations of sucrose (25~100 mM) for 1hr.
SGLT1, GLUT2, and GLUT5 mRNA levels were normalized to GAPDH as
housekeeping genes. Results are presented relative value compare to the control groups
as mean ± SD of three independent experiments (n=3). Different corresponding letters
indicate significant differences at p < 0.05 by Duncan’s test.
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Figure 12. Effects of sucrose on carbohydrate digesting enzyme expression. Human
intestinal Caco-2 cells were treated with different concentrations of sucrose (25 ~ 100
mM) for 1hr. S-I and M-G mRNA levels were normalized to GAPDH as housekeeping
genes. Results are presented relative value compare to the control groups as mean ± SD
of three independent experiments (n=3). Different corresponding letters indicate
significant differences at p < 0.05 by Duncan’s test.
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3.4.6 Effects of CBE and BBE on small intestinal ɑ-glucosidase, glucose
transporters, and glucose uptake in Caco-2 cells
Next, we investigated the effects of CBE and BBE on intestinal ɑ-glucosidase, glucose
transporters as well as glucose uptake in the presence of sucrose. Physiological effects
of CBE and BBE on human intestinal cells were determined by glucose uptake (Figure
13). In the presence of 100 mM of sucrose, glucose uptake was significantly increased,
which was markedly decreased in the presence of CBE or BBE.
Effect of CBE and BBE on glucose transporters and ɑ-glucosidase enzymes in the
presence of sucrose were determined. As shown in Figure 14, mRNA levels of SGLT1,
GLUT2, and GLUT5 were significance increased by 100 mM sucrose, which was
significantly attenuated in presence of CBE and BBE. Furthermore, S-I was elevated in
the presence of 100 mM of sucrose and was diminished in the presence of CBE or BBE.
In the case of the M-G, it was not altered in the presence of dietary sucrose but it was
downregulated by the CBE or BBE (Figure 15). These results suggest that CBE and
BBE may regulate postprandial hyperglycemia in high sucrose diet by modifying
glucose transporters as well as carbohydrate digesting enzymes.
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Figure 13. Effects of CBE and BBE on glucose uptake in the presence of sucrose.
Human intestinal Caco-2 intestinal cells were treated with 200 μg/mL of CBE or BBE
extracts in the presence of 100 mM of sucrose for 1hr. Glucose uptake was determined
by measuring fluorescence of 6-NBDG in the cells. Excitation and emission wavelength
for 6-NBDG is 465 nm and 540 nm respectively. Results are normalized to control
group and presented as mean ± SD of three independent experiments (n=3). CBE:
Cranberry extracts, BBE: Blackberry extracts
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Figure 14. Effects of CBE and BBE on glucose transporter expression in the
presence of sucrose. Human intestinal Caco-2 intestinal cells were treated with 200
μg/mL of CBE or BBE in the presence of sucrose (100 mM) for 1hr. SGLT1, GLUT2,
and GLUT5 mRNA levels were normalized to GAPDH as housekeeping genes. Results
are presented relative value compare to the control groups as mean ± SD of three
independent experiments (n=3). Different corresponding letters indicate significant
differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry
extracts. CBE: Cranberry extracts, BBE: Blackberry extracts
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Figure 15. Effects of sucrose on carbohydrate digesting enzyme expression in the
presence of sucrose. Human intestinal Caco-2 intestinal cells were treated with 200
μg/mL of CBE or BBE in the presence of sucrose (100 mM) for 1hr. S-I and M-G
mRNA levels were normalized to GAPDH as housekeeping genes. Results are
presented relative value compare to the control groups as mean ± SD of three
independent experiments (n=3). Different corresponding letters indicate significant
differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry
extracts. CBE: Cranberry extracts, BBE: Blackberry extracts
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3.4.7 Effects of sucralose on small intestinal ɑ-glucosidase, glucose transporters,
sweet-sensing receptors and glucose uptake in Caco-2 cells
Sucralose is one of artificial sweeteners that have been extensively used in various food
products and beverages as an alternative to dietary sucrose [9]. Although sucralose is
non-digestible and non-absorbable, there is evidence showing that dietary AS increased
intestinal glucose transporters [12]. However, effects of sucralose on intestinal
digestion and absorption are not currently known. Hence, the effect of sucralose was
evaluated with different concentrations selected based on daily accepted intake of
sucralose from FDA.
Glucose uptake was evaluated to identify physiological effects of sucralose on glucose
absorption in enterocytes. As shown in Figure 16, glucose uptake was not increased in
the presence of 1 mM sucralose but it was significantly elevated at 10 mM of sucralose
compared to control.
As shown in Figure 17, 10 mM of sucralose significantly elevated SGLT1 and GLUT2
expression significantly without altering GLUT5. Effects of sucralose on ɑ-glucosidase
activity and its mRNA expressions were evaluated. Unlike sucrose, both ɑ-glucosidase
activity and gene expression of S-I and M-G, was not altered in the presence of
sucralose (Figure 18). Expression of both sweet sensing receptors, T1R2 and T1R3 in
Caco-2 cells were also evaluated and were increased dose dependently (Figure 19).
Although molecular mechanisms between sweet-sensing receptors and SGLT1 are yet
to be identified, the expression of T1R2 and T1R3 mRNA was similarly increasing as
SGLT1 by sucralose treatment.
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Figure 16. Effects of sucralose on glucose uptake human Caco-2 intestinal cells were
treated with different concentration of sucralose for 1hr. Glucose uptake was
determined by measuring fluorescence of 6-NBDG in the cells. Excitation and emission
wavelength for 6-NBDG is 465 nm and 540 nm respectively. Results are normalized to
control group and presented as mean ± SD of three independent experiments (n=3).
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Figure 17. Effects of sucralose on glucose transporter expression. human Caco-2
intestinal cells were treated with different concentrations of sucralose (1, 10 mM) for
1hr. SGLT1, GLUT2, and GLUT5 mRNA levels were normalized to GAPDH as
housekeeping genes. Results are presented relative value compare to the control groups
as mean ± SD of three independent experiments (n=3). Different corresponding letters
indicate significant differences at p < 0.05 by Duncan’s test.
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Figure 18. Effects of sucralose on carbohydrate digesting enzyme expression.
Caco-2 cells were treated with different concentrations of sucralose (1, 10 mM) for 1hr.
S-I and M-G mRNA levels were normalized to GAPDH as housekeeping genes. Results
are presented relative value compare to the control groups as mean ± SD with three
independent experiments (n=3). Different corresponding letters indicate significant
differences at p < 0.05 by Duncan’s test.
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Figure 19. Effects of sucralose on sweet-sensing receptors expression. human Caco2 intestinal cells were treated with different concentrations of sucralose (1, 10 mM) for
1hr. T1R2 and T1R3 mRNA levels were normalized to GAPDH as housekeeping genes.
Results are presented relative value compare to the control groups as mean ± SD of
three independent experiments (n=3). Different corresponding letters indicate
significant differences at p < 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE:
Blackberry extracts.
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3.4.8 Effects of CBE and BBE on small intestinal ɑ-glucosidase, glucose
transporters, sweet-sensing receptors and glucose uptake in the presence of
sucralose in Caco-2 cells
To determine physiological effects CBE or BBE on enterocytes in the presence of 10
mM of sucralose, glucose uptake was performed (Figure 20). Compared to control, 10
mM sucralose elevated glucose uptake by 10%, but suppressed in the presence of 200
μg/mL of CBE or BBE.
Next, we evaluated the molecular mechanisms of CBE and BBE on intestinal digestive
enzymes and sweet-sensing receptors in the presence of 10 mM of sucralose. As shown
in Figure 22, BBE suppressed all glucose transporters, SGLT1, GLUT2, and GLUT5,
whereas CBE only suppressed GLUT2 and GLUT 5 without effect on the SGLT1
expression in presence of 10 mM of sucralose. Furthermore, sweet-sensing receptors,
T1R2 and T1R3, were elevated in presence of sucralose and were attenuated in the
presence of 200 μg/mL of CBE or BBE (Figure 23). Moreover, between CBE and BBE,
BBE had higher inhibitory effects on the T1R2 expression than CBE. As shown in
previous results, sucralose did not affect the expression of carbohydrate- digesting
enzymes. However, CBE and BBE suppressed S-I, and M-G mRNA expression (Figure
22).
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Figure 20. Effects of CBE and BBE on glucose uptake in the presence of sucralose.
Human intestinal Caco-2 cells were treated with 200 μg/mL of CBE or BBE extracts in
presence of 10 mM of sucralose for 1hr. Glucose uptake was determined by measuring
fluorescence of 6-NBDG in the cells. Excitation and emission wavelength for 6-NBDG
is 465 nm and 540 nm respectively. Results are normalized to control group and
presented as mean ± SD of three independent experiments (n=3). CBE: Cranberry
extracts, BBE: Blackberry extracts.
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Figure 21. Effects of CBE and BBE on glucose transporter expression in the
presence of sucralose Human intestinal Caco-2were treated with 200 μg/mL of CBE
or BBE in presence of sucralose (10 mM) for 1hr. SGLT1, GLUT2, and GLUT5 mRNA
levels were normalized to GAPDH as housekeeping genes. Results are presented
relative value compare to the control groups as mean ± SD of three independent
experiments (n=3). Different corresponding letters indicate significant differences at p
< 0.05 by Duncan’s test. CBE: Cranberry extracts, BBE: Blackberry extracts.
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Figure 22. Effects of sucrose on carbohydrate digesting enzyme expression in the
presence of sucralose. Human intestinal Caco-2 were treated with 200 μg/mL of CBE
or BBE in presence of sucralose (10 mM) for 1hr. S-I and M-G mRNA levels were
normalized to GAPDH as housekeeping genes. Results are presented relative value
compare to the control groups as mean ± SD of three independent experiments (n=3).
Different corresponding letters indicate significant differences at p < 0.05 by Duncan’s
test. CBE: Cranberry extracts, BBE: Blackberry extracts. CBE: Cranberry extracts,
BBE: Blackberry extracts.
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Figure 23. Effects of sucrose on sweet-sensing receptors expression in the presence
of sucralose. Human intestinal Caco-2 were treated with 200 μg/mL of CBE or BBE in
presence of sucralose (10 mM) for 1hr. T1R2 and T1R3 mRNA levels were normalized
to GAPDH as housekeeping genes. Results are presented relative value compare to the
control groups as mean ± SD of three independent experiments (n=3). Different
corresponding letters indicate significant differences at p < 0.05 by Duncan’s test. CBE:
Cranberry extracts, BBE: Blackberry extracts.
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3.4.9 Conclusion
In the current study, cranberry and blackberry extracts were evaluated for potential
benefits against postprandial hyperglycemia, a key metabolic feature of T2DM and its
complication. Our finding showed significant evidence of CBE and BBE in lowering
plasma levels after a meal. In particular, we found that both CBE and BBE reduced
glucose uptake in the presence of sucrose and sucralose in human intestinal Caco-2 cell
line. The ability of CBE and BBE to prevent sucrose and sucralose-induced intestinal
glucose uptake is associated with inhibition of ɑ-glucosidase activity as well as gene
expression. Notably, BBE with higher total phenolic contents than CBE showed ɑglucosidase inhibitory activity with no effects on glucose transporters, while CBE
showed inhibitory actions on both. These results show that certain berries exhibit more
potential for the prevention of postprandial hyperglycemia than others, indicating that
specific profile of nutrients and/or phenolic compounds present in different berries is
of importance for the observed cellular effects.
Current findings also suggest the involvement of sweet-sensing receptors as potential
upstream targets that regulate glucose transport and uptake. Taken together, our results
suggest that increased intake of berries may be a promising strategy to delay
postprandial glucose flux into the system and has important implications in the
prevention of T2DM & its complications. However, the potential benefits of berry
extracts need to be verified in in vivo and clinical studies in order to confirm the
physiological relevance of current findings.
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